CUTISS AG has yielded positive results from the Phase 2 clinical trial of its lead product denovoSkin, in adult and adolescent burn patients and phase 1 in children. Safety and efficacy of denovoSkin have been confirmed. The medtech solution is a personalized, bio-engineered dermo-epidermal skin substitute for patients requiring a skin graft due to a major burn.
Daniela Marino, CEO of CUTISS said “We are proud of the progress made this far and the hard work and dedication of the entire CUTISS team. We look forward to preparing for the next regulatory steps to bring this promising treatment to patients suffering from severe burns and skin injuries.”